Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: Implication of c-Src and its inhibitor

International Journal of Oncology

Volumn 34, Issue 3, 2009, Pages 689-696

  Ueda, Yasuto ^a   Igishi, Tadashi ^a   Hashimoto, Kiyoshi ^a   Suyama, Hisashi ^a   Araki, Kunio ^b   Sumikawa, Takashi ^a   Takeda, Kenichi ^a   Nakazaki, Hirofumi ^a   Matsunami, Keniji ^a   Kodani, Masahiro ^a   Shigeoka, Yasushi ^a   Matsumoto, Shingo ^a   Shimizu, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Matsue National Hospital   (China)

Author keywords

Akt; Amrubicin; c Src; Dasatinib; Small cell lung cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMRUBICIN; CISPLATIN; DASATINIB; ETOPOSIDE; GENISTEIN; PROTEIN KINASE B; PROTEIN KINASE P60; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GROWTH INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SRC-FAMILY KINASES;

EID: 64549096030     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000195     Document Type: Article

References (37)

1. Simon GR and Turrisi A: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 324S-339S, 2007.
2. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
3. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B and Sandler A: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24: 2038-2043, 2006.
4. Schiller JH: Topotecan in small cell lung cancer. Semin Oncol 24: S20-S27-S20-S33, 1997.
5. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR and Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658-667, 1999.
6. Argiris A and Murren JR: Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents. Cancer J 7: 228-235, 2001.
7. Ettinger DS: Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? J Thorac Oncol 2: 160-165, 2007.
8. Fischer B and Arcaro A: Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials 3: 40-61, 2008.
9. Talapatra S and Thompson CB: Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 298: 873-878, 2001.
10. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
11. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003.
12. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS and Li W: PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 21: 5289-5300, 2002.
13. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS and Shepherd FA: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241-2247, 2003.
14. Kim D, Cheng GZ, Lindsley CW, Yang H and Cheng JQ: Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 6: 1250-1258, 2005.
15. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE and Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19: 3521-3528, 2000.
16. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M and Heelan RT: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103: 2128-2131, 2005.
17. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR and Adjei AA: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16: 1811-1816, 2005.
18. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R and Le Chevalier T: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9: 5880-5887, 2003.
19. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
20. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001.
21. Roelle S, Grosse R, Buech T, Chubanov V and Gudermann T: Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells. Oncogene 27: 1737-1748, 2008.
22. Steinberg M: Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29: 2289-2308, 2007.
23. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97: 368-377, 2007.
24. Arcaro A, Aubert M, Espinosa del Hierro ME, Khanzada UK, Angelidou S, Tetley TD, Bittermann AG, Frame MC and Seckl MJ: Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal 19: 1081-1092, 2007.
25. Fischer B, Marinov M and Arcaro A: Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33: 391-406, 2007.
26. Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C and Krystal GW: The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 3: 527-535, 2004.
27. Worden FP and Kalemkerian GP: Therapeutic advances in small cell lung cancer. Expert Opin Investig Drugs 9: 565-579, 2000.
28. Mazurenko NN, Kogan EA, Zborovskaya IB and Kisseljov FL: Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28: 372-377, 1992.
29. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J and Cortes J: Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112: 516-518, 2008.
30. von Mehren M: Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer 6 (Suppl 1): S30-S34, 2006.
31. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ 'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319-326, 2007.
32. Micke P, Basrai M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R and Hengstler JG: Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 9: 188-194, 2003.
33. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448, 1994.
34. Ookawa K, Shiseki M, Takahashi R, Yoshida Y, Terada M and Yokota J: Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 8: 2175-2181, 1993.
35. Bondzi C, Litz J, Dent P and Krystal GW: Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retino-blastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth Differ 11: 305-314, 2000.
36. Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K and Kohno M: Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochem Biophys Res Commun 340: 560-566, 2006.
37. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, Qi YL, Deng Q, Cao J, Liu SQ, Luo HS and Yu JP: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 122: 433-443, 2008.